Germacrone cooperates with dexmedetomidine to alleviate high‑fat diet‑induced type 2 diabetes mellitus via upregulating AMPKα1 expression Retraction in /10.3892/etm.2024.12406

Sun,Yang; Li,Lanlan; Wu,Jun; Gong,Bing; Liu,Haiyan

doi:10.3892/etm.2019.7990

Germacrone cooperates with dexmedetomidine to alleviate high‑fat diet‑induced type 2 diabetes mellitus via upregulating AMPKα1 expression

Retraction in: /10.3892/etm.2024.12406

Authors:
- Yang Sun
- Lanlan Li
- Jun Wu
- Bing Gong
- Haiyan Liu
View Affiliations

Affiliations: Department of Anesthesia, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150000, P.R. China
Published online on: September 9, 2019 https://doi.org/10.3892/etm.2019.7990
Pages: 3514-3524
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of germacrone (GM) and dexmedetomidine (DEX) in treating type 2 diabetes mellitus (T2DM). A high‑fat diet (HFD)‑induced T2DM rat model was established. The experimental rats were divided into the control group, HFD group, GM treatment group, DEX treatment group and GM + DEX treatment group. In addition, adenosine monophosphate‑activated protein kinase (AMPK) inhibitor compound C (CC) was used to inhibit AMPKα1 expression. All rats received their respective treatment daily for 21 days. Blood glucose and lipid levels, apoptosis of hepatic cells, and levels of inflammatory factors and oxidative stress indicators in serum samples were evaluated. Protein expression of AMPKα1 and its downstream targets were also investigated. Results demonstrated that blood glucose concentration, blood lipid indicators (endothelin, total cholesterol, triglyceride and low density lipoprotein cholesterol), cell apoptosis in liver tissues, total oxidant status, malondialdehyde, interleukin (IL)‑6, tumor necrosis factor‑α (TNF‑α) and IL‑1β levels in serum were increased in the high‑fat group compared to the control but decreased following GM and/or DEX treatment. By contrast, high‑density lipoprotein cholesterol and antioxidative stress indicator superoxide dismutase (SOD) were decreased in the high‑fat group but increased following GM and/or DEX treatment. Protein expression of AMPKα1 and the catabolic genes carnitine palmitoyltransferase‑1, peroxisome proliferator‑activated receptor‑α and acyl coenzyme A were decreased whilst anabolic genes, including sterol regulatory element binding protein‑1c, fatty acid synthase and diacylglycerol acyltransferase‑2, were increased in the HFD group. These effects were attenuated by GM and/or DEX treatment. AMPKα1 inhibition resulted in decreased SOD and increased cell apoptosis in liver tissues as well as increased IL‑6, TNF‑α and IL‑1β levels compared with the HFD group. However, these effects were abolished following treatment with CC, GM and DEX together. Taken together these results indicated that GM worked synergistically with DEX to attenuate symptoms of high‑fat‑induced T2DM, with the effect potentially involving an increase in AMPKα1 expression.

View Figures

View References

1	Basciano H, Federico L and Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond). 2:52005. View Article : Google Scholar : PubMed/NCBI
2	Zimmet PZ, Magliano DJ, Herman WH and Shaw JE: Diabetes: A 21st century challenge. Lancet Diabetes Endocrinol. 2:56–64. 2014. View Article : Google Scholar : PubMed/NCBI
3	Musso G, Gambino R and Cassader M: Non-alcoholic fatty liver disease from pathogenesis to management: An update. Obes Rev. 11:430–445. 2010. View Article : Google Scholar : PubMed/NCBI
4	Rivera CA: Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology. 15:109–114. 2008. View Article : Google Scholar : PubMed/NCBI
5	Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, Chen B, Li X, Zu M, Zhou D, et al: Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol. 685:156–164. 2012. View Article : Google Scholar : PubMed/NCBI
6	Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, Gorrell MD, Yue DK and Twigg SM: Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 55:435–444. 2011. View Article : Google Scholar : PubMed/NCBI
7	Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 414:813–820. 2001. View Article : Google Scholar : PubMed/NCBI
8	Sada K, Nishikawa T, Kukidome D, Yoshinaga T, Kajihara N, Sonoda K, Senokuchi T, Motoshima H, Matsumura T and Araki E: Hyperglycemia induces cellular hypoxia through production of mitochondrial ROS followed by suppression of aquaporin-1. PLoS One. 11:e01586192016. View Article : Google Scholar : PubMed/NCBI
9	Maritim AC, Sanders RA and Watkins JB III: Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol. 17:24–38. 2003. View Article : Google Scholar : PubMed/NCBI
10	Dubey R, Minj P, Malik N, Sardesai DM, Kulkarni SH, Acharya JD, Bhavesh NS, Sharma S and Kumar A: Recombinant human islet amyloid polypeptide forms shorter fibrils and mediates β-cell apoptosis via generation of oxidative stress. Biochem J. 474:3915–3934. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ige AO and Adewoye EO: Oral magnesium treatment reduces anemia and levels of inflammatory markers in experimental diabetes. J Diet Suppl. 14:76–88. 2017. View Article : Google Scholar : PubMed/NCBI
12	Attie AD and Scherer PE: Adipocyte metabolism and obesity. J Lipid Res. 50 (Suppl):S395–S399. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen L, Chen R, Wang H and Liang F: Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015:5084092015. View Article : Google Scholar : PubMed/NCBI
14	Feldman EL, Nave KA, Jensen TS and Bennett DLH: New horizons in diabetic neuropathy: Mechanisms, bioenergetics, and pain. Neuron. 93:1296–1313. 2017. View Article : Google Scholar : PubMed/NCBI
15	Jaakola ML, Salonen M, Lehtinen R and Scheinin H: The analgesic action of dexmedetomidine-a novel alpha 2-adrenoceptor agonist-in healthy volunteers. Pain. 46:281–285. 1991. View Article : Google Scholar : PubMed/NCBI
16	Kip G, Çelik A, Bilge M, Alkan M, Kiraz HA, Özer A, Şıvgın V, Erdem Ö, Arslan M and Kavutçu M: Dexmedetomidine protects from post-myocardial ischaemia reperfusion lung damage in diabetic rats. Libyan J Med. 10:278282015. View Article : Google Scholar
17	Zeng X, Wang H, Xing X, Wang Q and Li W: Dexmedetomidine protects against transient global cerebral ischemia/reperfusion induced oxidative stress and inflammation in diabetic rats. PLoS One. 11:e01516202016. View Article : Google Scholar : PubMed/NCBI
18	Ma XD, Li BP, Wang DL and Yang WS: Postoperative benefits of dexmedetomidine combined with flurbiprofen axetil after thyroid surgery. Exp Ther Med. 14:2148–2152. 2017. View Article : Google Scholar : PubMed/NCBI
19	Qian XL, Zhang W, Liu MZ, Zhou YB, Zhang JM, Han L, Peng YM, Jiang JH and Wang QD: Dexmedetomidine improves early postoperative cognitive dysfunction in aged mice. Eur J Pharmacol. 746:206–212. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wu J, Feng Y, Han C, Huang W, Shen Z, Yang M, Chen W and Ye L: Germacrone derivatives: Synthesis, biological activity, molecular docking studies and molecular dynamics simulations. Oncotarget. 8:15149–15158. 2017.PubMed/NCBI
21	Xie XH, Zhao H, Hu YY and Gu XD: Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells. Exp Ther Med. 8:1611–1615. 2014. View Article : Google Scholar : PubMed/NCBI
22	Chen QF, Wang G, Tang LQ, Yu XW, Li ZF and Yang XF: Effect of germacrone in alleviating HUVECs damaged by H₂O₂-induced oxidative stress. Zhongguo Zhong Yao Za Zhi. 42:3564–3571. 2017.(In Chinese). PubMed/NCBI
23	Guo YR and Choung SY: Germacrone attenuates hyperlipidemia and improves lipid metabolism in high-fat diet-induced obese C57BL/6J mice. J Med Food. 20:46–55. 2017. View Article : Google Scholar : PubMed/NCBI
24	Seo E, Park EJ, Joe Y, Kang S, Kim MS, Hong SH, Park MK, Kim DK, Koh H and Lee HJ: Overexpression of AMPKalpha1 ameliorates fatty liver in hyperlipidemic diabetic rats. Korean J Physiol Pharmacol. 13:449–454. 2009. View Article : Google Scholar : PubMed/NCBI
25	Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the care and use of laboratory animals (Eighth edition)The National Academies Press; Washington, D.C.: 2011
26	Li J, Feng J, Wei H, Liu Q, Yang T, Hou S, Zhao Y, Zhang B and Yang C: The aqueous extract of Gynura divaricata (L.) DC. improves glucose and lipid metabolism and ameliorates type 2 diabetes mellitus. Evid Based Complement Alternat Med. 2018:86862972018.PubMed/NCBI
27	Brunt EM: Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis. 21:3–16. 2001. View Article : Google Scholar : PubMed/NCBI
28	Yagi S, Doorschodt BM, Afify M, Klinge U, Kobayashi E, Uemoto S and Tolba RH: Improved preservation and microcirculation with POLYSOL after partial liver transplantation in rats. J Surg Res. 167:e375–e383. 2011. View Article : Google Scholar : PubMed/NCBI
29	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
30	Michurina SV, Ischenko IY, Arkhipov SA, Klimontov VV, Cherepanova MA, Korolev MA, Rachkovskaya LN, Zav'yalov EL and Konenkov VI: Melatonin-aluminum oxide-polymethylsiloxane complex on apoptosis of liver cells in a Model of obesity and type 2 diabetes mellitus. Bull Exp Biol Med. 164:165–169. 2017. View Article : Google Scholar : PubMed/NCBI
31	Lee SY, Ku HC, Kuo YH, Chiu HL and Su MJ: Pyrrolidinyl caffeamide against ischemia/reperfusion injury in cardiomyocytes through AMPK/AKT pathways. J Biomed Sci. 22:182015. View Article : Google Scholar : PubMed/NCBI
32	Zhang C, Huang Z, Gu J, Yan X, Lu X, Zhou S, Wang S, Shao M, Zhang F, Cheng P, et al: Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia. 58:1937–1948. 2015. View Article : Google Scholar : PubMed/NCBI
33	Yang H, Feng A, Lin S, Yu L, Lin X, Yan X, Lu X and Zhang C: Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis. 9:2272018. View Article : Google Scholar : PubMed/NCBI
34	Yang P, Pei Q, Yu T, Chang Q, Wang D, Gao M, Zhang X and Liu Y: Compromised wound healing in ischemic type 2 diabetic rats. PLoS One. 11:e01520682016. View Article : Google Scholar : PubMed/NCBI
35	Wang RR, Chen XY, Liao HL, Wan L, Li JM, Chen LL, Chen XF and Chen GR: The relationship between the expression of NF-kB, TGFbeta1, FN and hepatic fibrosis in diabetic rats. Zhonghua Gan Zang Bing Za Zhi. 18:194–198. 2010.(In Chinese). PubMed/NCBI
36	Kotronen A and Yki-Järvinen H: Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 28:27–38. 2008. View Article : Google Scholar : PubMed/NCBI
37	Cusi K: Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 16:141–149. 2009. View Article : Google Scholar : PubMed/NCBI
38	Zhou H, Fang C, Zhang L, Deng Y, Wang M and Meng F: Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. Chin Med J (Engl). 127:225–231. 2014.PubMed/NCBI
39	Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Brooks B, Bu Y, Cavanagh E, Raleigh J, McLennan SV, et al: Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes. 7:809–819. 2015. View Article : Google Scholar : PubMed/NCBI
40	Tourigny A, Charbonneau F, Xing P, Boukrab R, Rousseau G, St-Arnaud R and Brezniceanu ML: CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. PLoS One. 7:e486522012. View Article : Google Scholar : PubMed/NCBI
41	Samikkannu T, Thomas JJ, Bhat GJ, Wittman V and Thekkumkara TJ: Acute effect of high glucose on long-term cell growth: A role for transient glucose increase in proximal tubule cell injury. Am J Physiol Renal Physiol. 291:F162–F175. 2006. View Article : Google Scholar : PubMed/NCBI
42	Das M and Manna K: Chalcone scaffold in anticancer armamentarium: A molecular insight. J Toxicol. 2016:76510472016. View Article : Google Scholar : PubMed/NCBI
43	Romagnoli R, Baraldi PG, Cruz-Lopez O, Lopez Cara C, Carrion MD, Brancale A, Hamel E, Chen L, Bortolozzi R, Basso G and Viola G: Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues. J Med Chem. 53:4248–4258. 2010. View Article : Google Scholar : PubMed/NCBI
44	Bonner C, Bacon S, Concannon CG, Rizvi SR, Baquié M, Farrelly AM, Kilbride SM, Dussmann H, Ward MW, Boulanger CM, et al: INS-1 cells undergoing caspase-dependent apoptosis enhance the regenerative capacity of neighboring cells. Diabetes. 59:2799–2808. 2010. View Article : Google Scholar : PubMed/NCBI
45	Ahmed FF, Abd El-Hafeez AA, Abbas SH, Abdelhamid D and Abdel-Aziz M: New 1,2,4-triazole-Chalcone hybrids induce Caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. Eur J Med Chem. 151:705–722. 2018. View Article : Google Scholar : PubMed/NCBI
46	Gerber PA and Rutter GA: The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxid Redox Signal. 26:501–518. 2017. View Article : Google Scholar : PubMed/NCBI
47	Styskal J, Van Remmen H, Richardson A and Salmon AB: Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med. 52:46–58. 2012. View Article : Google Scholar : PubMed/NCBI
48	Chen H, Yu M, Li M, Zhao R, Zhu Q, Zhou W, Lu M, Lu Y, Zheng T, Jiang J, et al: Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease. Mol Cell Biochem. 363:85–91. 2012. View Article : Google Scholar : PubMed/NCBI
49	Earle KA, Zitouni K, Pepe J, Karaflou M and Godbold J Jr: Modulation of endogenous antioxidant defense and the progression of kidney disease in multi-heritage groups of patients with type 2 diabetes: PRospective EValuation of Early Nephropathy and its Treatment (PREVENT). J Transl Med. 14:2342016. View Article : Google Scholar : PubMed/NCBI
50	Mohammedi K, Patente TA, Bellili-Muñoz N, Driss F, Monteiro MB, Roussel R, Pavin EJ, Seta N, Fumeron F, Azevedo MJ, et al: Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. Diabetologia. 56:2733–2742. 2013. View Article : Google Scholar : PubMed/NCBI
51	Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z and Ruderman N: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 54:3458–3465. 2005. View Article : Google Scholar : PubMed/NCBI
52	Das A and Mukhopadhyay S: The evil axis of obesity, inflammation and type-2 diabetes. Endocr Metab Immune Disord Drug Targets. 11:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
53	Goldfine AB, Fonseca V and Shoelson SE: Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem. 57:162–167. 2011. View Article : Google Scholar : PubMed/NCBI
54	Zhang C, Lu X, Tan Y, Li B, Miao X, Jin L, Shi X, Zhang X, Miao L, Li X and Cai L: Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model. PLoS One. 7:e492572012. View Article : Google Scholar : PubMed/NCBI
55	Pan HY, Guo L and Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 88:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
56	Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N and Maulik G: Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease-an overview. Toxicol Mech Methods. 22:330–335. 2012. View Article : Google Scholar : PubMed/NCBI
57	Sukriti S, Tauseef M, Yazbeck P and Mehta D: Mechanisms regulating endothelial permeability. Pulm Circ. 4:535–551. 2014. View Article : Google Scholar : PubMed/NCBI
58	Ma X, Zhang J, Deng R, Ding S, Gu N and Guo X: Synergistic effect of smoking with genetic variants in the AMPKalpha1 gene on the risk of coronary artery disease in type 2 diabetes. Diabetes Metab Res Rev. 30:483–488. 2014. View Article : Google Scholar : PubMed/NCBI